Castle Biosciences (CSTL) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue rose 74% year-over-year to $87 million, with test report volume up 49% to 25,102, driven by strong growth across dermatology, gastroenterology, and mental health test portfolios.

• Net income for Q2 2024 was $8.9 million, reversing a net loss of $18.8 million in Q2 2023, reflecting improved operating leverage and revenue growth.

• Full-year 2024 revenue guidance increased to $275–$300 million, up from $255–$265 million, reflecting 25–36% year-over-year growth.

• The company focuses on innovative diagnostic tests in dermatology, gastroenterology, mental health, and ophthalmology, supported by robust clinical evidence and peer-reviewed validation.

• Strategy centers on building evidence, best-in-class tests, and market penetration to drive value creation.

Financial highlights

• Q2 2024 net revenues: $87 million, up 74% year-over-year; adjusted revenues: $86.6 million, up 72%.

• Gross margin improved to 80.7% (adjusted: 83.2%) from 73.5% (adjusted: 78%) year-over-year.

• Net income was $8.9 million; diluted EPS was $0.31, versus a loss per share of $0.70 last year.

• Adjusted EBITDA reached $21.5 million, up from -$5.3 million a year ago.

• Cash, cash equivalents, and marketable securities totaled $259.7 million at quarter end.

Outlook and guidance

• 2024 revenue guidance raised to $275–$300 million, reflecting strong H1 performance and up from $255–$265 million.

• Guidance assumes no CMS coverage for DecisionDx-SCC in Q4 2024 and no change in ASP.

• Aims to achieve operating cash flow positivity by the end of 2025, with continued robust test volume growth and strong adjusted gross margin.

• Pipeline expansion includes an inflammatory skin disease test targeted for launch by end of 2025.

• Management expects continued commercial momentum and portfolio growth.